Home › Companies › AXSOME THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and AXSOME THERAPEUTICS INC.’s Form 8-K, filed 2025-06-09 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore AXSOME THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are AXSOME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-09 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Roger A. Jeffs, Ph.D. | 27,307,185 | -- | -- | 8,050,959 | 6,010,496 | Majority: yes |
| Proposal 2: Approval of the Company's 2025 Long-Term Incentive Plan | 26,403,625 | 8,893,068 | 61,451 | -- | 6,010,496 | Majority: yes |
| Proposal 3: Ratification of Appointment of Deloitte & Touche LLP | 40,849,740 | 225,677 | 293,223 | -- | 0 | Majority: yes |
| Proposal 4: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers | 34,776,343 | 528,199 | 53,602 | -- | 6,010,496 | Majority: yes |
Source: AXSOME THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-09 — read the filing on EDGAR.
Each item below shows how the 345 asset managers that disclosed a AXSOME THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AXSOME THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2025-06-06.
Combines 11 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
AXSOME THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 34,776,343 for, 528,199 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,216,759 outstanding shares: 71% for, 1% against (72% of the company cast a for/against vote).
The 338 asset managers below cast 99.1% of the shares they voted on this item FOR (30,050,988 for, 259,245 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,920,466 | 311 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 2,826,708 | 0 | 0 | 0 | For |
| Fidelity | 2,516,789 | 0 | 0 | 0 | For |
| BlackRock | 1,980,873 | 0 | 0 | 0 | For |
| BVF INC/IL | 1,690,221 | 0 | 0 | 0 | For |
| Invesco | 1,475,889 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1,032,719 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 941,646 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 815,176 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 742,065 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 705,954 | 0 | 0 | 0 | For |
| Charles Schwab | 681,782 | 0 | 0 | 0 | For |
| T. Rowe Price | 522,732 | 0 | 0 | 0 | For |
| Putnam | 486,132 | 0 | 0 | 0 | For |
| Nuveen | 482,877 | 0 | 0 | 0 | For |
| Wellington | 481,123 | 0 | 0 | 0 | For |
| State Street | 469,933 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 423,440 | 0 | 0 | 0 | For |
| Loomis Sayles | 411,010 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 399,200 | 0 | 0 | 0 | For |
| TIAA | 381,193 | 0 | 0 | 0 | For |
| Man Group plc | 334,690 | 0 | 0 | 0 | For |
| 1832 Asset Management L.P. | 320,700 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 300,000 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 297,444 | 0 | 0 | 0 | For |
Showing the 25 largest of 338 asset managers. See all 338 in the interactive database.
Meeting held 2025-06-06.
Combines 3 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
AXSOME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roger A. Jeffs, Ph.D.”): 27,307,185 for, 8,050,959 withheld, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,216,759 outstanding shares: 55% for, 16% withheld (72% of the company cast a for/withheld vote).
The 93 asset managers below cast 100% of the shares they voted on this item FOR (8,265,347 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,805,597 | 0 | 311 | 0 | For |
| Fidelity | 1,568,223 | 0 | 0 | 0 | For |
| BlackRock | 992,353 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 742,065 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 705,954 | 0 | Abstain |
| Invesco | 0 | 0 | 689,907 | 0 | Abstain |
| TIAA | 0 | 0 | 381,193 | 0 | Abstain |
| Charles Schwab | 340,860 | 0 | 0 | 0 | For |
| Putnam | 200,650 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 199,412 | 0 | Abstain |
| Loomis Sayles | 0 | 0 | 162,529 | 0 | Abstain |
| Waddell & Reed | 0 | 0 | 139,244 | 0 | Abstain |
| Principal | 129 | 0 | 137,700 | 0 | Abstain |
| Equitable | 91,653 | 0 | 45,190 | 0 | For |
| Hartford | 95,992 | 0 | 0 | 0 | For |
| Jackson National | 60,290 | 0 | 28,911 | 0 | For |
| Aberdeen | 0 | 0 | 81,916 | 0 | Abstain |
| Lincoln Financial | 27,100 | 0 | 44,031 | 0 | Abstain |
| DWS | 0 | 0 | 65,679 | 0 | Abstain |
| First Trust | 0 | 0 | 64,278 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 62,747 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 0 | 0 | 61,282 | 0 | Abstain |
| Voya | 0 | 0 | 56,802 | 0 | Abstain |
| CARILLON SERIES TRUST | 0 | 0 | 55,770 | 0 | Abstain |
| Nuveen | 0 | 0 | 48,397 | 0 | Abstain |
Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.
Meeting held 2025-06-06.
Combines 2 wordings of this item as funds reported it.
75% Majority: yes · of votes cast
AXSOME THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Approval of the Company's 2025 Long-Term Incentive Plan”): 26,403,625 for, 8,893,068 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,216,759 outstanding shares: 53.6% for, 18% against (72% of the company cast a for/against vote).
The 92 asset managers below cast 71% of the shares they voted on this item FOR (8,318,114 for, 3,394,090 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,805,908 | 0 | 0 | 0 | For |
| Fidelity | 1,568,223 | 0 | 0 | 0 | For |
| BlackRock | 992,353 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 742,065 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 705,954 | 0 | 0 | Against |
| Invesco | 0 | 689,907 | 0 | 0 | Against |
| TIAA | 0 | 381,193 | 0 | 0 | Against |
| Charles Schwab | 340,860 | 0 | 0 | 0 | For |
| Putnam | 0 | 200,650 | 0 | 0 | Against |
| T. Rowe Price | 187,774 | 11,638 | 0 | 0 | For |
| Loomis Sayles | 162,529 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 139,244 | 0 | 0 | Against |
| Principal | 129 | 137,700 | 0 | 0 | Against |
| Equitable | 91,653 | 45,190 | 0 | 0 | For |
| Hartford | 95,992 | 0 | 0 | 0 | For |
| Jackson National | 0 | 89,201 | 0 | 0 | Against |
| Aberdeen | 0 | 81,916 | 0 | 0 | Against |
| Lincoln Financial | 0 | 71,131 | 0 | 0 | Against |
| DWS | 0 | 65,679 | 0 | 0 | Against |
| First Trust | 0 | 64,278 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 62,747 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 61,282 | 0 | 0 | 0 | For |
| Voya | 0 | 56,802 | 0 | 0 | Against |
| CARILLON SERIES TRUST | 0 | 55,770 | 0 | 0 | Against |
| Nuveen | 0 | 48,397 | 0 | 0 | Against |
Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.
Meeting held 2025-06-06.
Combines 2 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
AXSOME THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Ratification of Appointment of Deloitte & Touche LLP”): 40,849,740 for, 225,677 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,216,759 outstanding shares: 83% for, 0.5% against (83% of the company cast a for/against vote).
The 92 asset managers below cast 99.8% of the shares they voted on this item FOR (11,738,695 for, 18,973 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,805,908 | 0 | 0 | 0 | For |
| Fidelity | 1,568,223 | 0 | 0 | 0 | For |
| BlackRock | 992,353 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 742,065 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 705,954 | 0 | 0 | 0 | For |
| Invesco | 689,907 | 0 | 0 | 0 | For |
| TIAA | 381,193 | 0 | 0 | 0 | For |
| Charles Schwab | 340,860 | 0 | 0 | 0 | For |
| Putnam | 200,650 | 0 | 0 | 0 | For |
| T. Rowe Price | 199,412 | 0 | 0 | 0 | For |
| Loomis Sayles | 162,529 | 0 | 0 | 0 | For |
| Waddell & Reed | 139,244 | 0 | 0 | 0 | For |
| Principal | 137,829 | 0 | 0 | 0 | For |
| Equitable | 136,843 | 0 | 0 | 0 | For |
| Hartford | 95,992 | 0 | 0 | 0 | For |
| Jackson National | 89,201 | 0 | 0 | 0 | For |
| Aberdeen | 81,916 | 0 | 0 | 0 | For |
| Lincoln Financial | 71,131 | 0 | 0 | 0 | For |
| DWS | 65,679 | 0 | 0 | 0 | For |
| First Trust | 64,278 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 62,747 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 61,282 | 0 | 0 | 0 | For |
| Voya | 56,802 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 55,770 | 0 | 0 | 0 | For |
| Nuveen | 48,397 | 0 | 0 | 0 | For |
Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.
Meeting held 2025-06-06.
0% fund support · no official result
The 3 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 28,556 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GuideStone | 0 | 24,062 | 0 | 0 | Against |
| VALUED ADVISERS TRUST | 0 | 3,618 | 0 | 0 | Against |
| HC CAPITAL TRUST | 0 | 876 | 0 | 0 | Against |
Meeting held 2025-06-06.
99% Majority: yes · of votes cast
AXSOME THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 34,776,343 for, 528,199 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,216,759 outstanding shares: 71% for, 1% against (72% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (19 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Simplify Exchange Traded Funds | 19 | 0 | 0 | 0 | For |
| SCHOLTZ & COMPANY, LLC | 0 | 0 | 0 | 0 | -- |
Meeting held 2025-06-06.
99.4% Majority: yes · of votes cast
AXSOME THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Ratification of Appointment of Deloitte & Touche LLP”): 40,849,740 for, 225,677 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,216,759 outstanding shares: 83% for, 0.5% against (83% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (556 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Virtus | 537 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 19 | 0 | 0 | 0 | For |
Meeting held 2024-06-07 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
AXSOME THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 32,850,943 for, 866,046 against, per its Form 8-K filed 2024-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,216,759 outstanding shares: 67% for, 2% against (69% of the company cast a for/against vote).
The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 15 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| COLDSTREAM CAPITAL MANAGEMENT INC | 0 | 15 | 0 | 0 | Against |
| Echo45 Advisors LLC | 0 | 0 | 0 | 0 | -- |
Ranked by the number of AXSOME THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 49,216,759 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.97% |
| 2 | RTW INVESTMENTS, LP | 5.74% |
| 3 | Fidelity | 5.11% |
| 4 | BlackRock | 4.02% |
| 5 | BVF INC/IL | 3.43% |
| 6 | Invesco | 3.00% |
| 7 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 2.10% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.91% |
| 9 | Fairmount Funds Management LLC | 1.66% |
| 10 | MUTUAL FUND SERIES TRUST | 1.51% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Herriot Tabuteau, M.D. | 19.01% | DEF14A |
| Antecip Capital LLC | 14.92% | DEF14A |
| Vanguard Group | 7.88% | 13F |
| BlackRock | 7.16% | 13F |
| RTW Investments, LP | 3.08% | 13G |
| FMR (Fidelity) | 2.53% | 13F |
| Geode Capital | 1.90% | 13F |
| State Street | 1.84% | 13F |
| Invesco | 1.74% | 13F |
| Wellington Management | 1.43% | 13F |
Percentages above are of 49,216,759 shares outstanding, as reported by AXSOME THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AXSOME THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At AXSOME THERAPEUTICS INC.'s shareholder meeting held 2025-06-06, in the 2024-2025 proxy season, 345 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,527 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the compensation of our named executive officers. — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AXSOME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-09.
AXSOME THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.